Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

@inproceedings{Talpaz2013InterimAO,
  title={Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts},
  author={Moshe Talpaz and Ronald L. Paquette and Lawrence B. Afrin and Solomon I Hamburg and Josef T Prchal and Katarzyna Jamieson and Howard Terebelo and Gregory L Ortega and Roger M. Lyons and Ram{\'o}n V. Tiu and Elliott F. Winton and Kavita Natrajan and Olatoyosi M. Odenike and David F. Claxton and Wei Peng and Peter O’Neill and Susan K Erickson-Viitanen and Lance Leopold and Victor A Sandor and Richard S. Levy and Hagop M Kantarjian and Srdan Verstovsek},
  booktitle={Journal of hematology & oncology},
  year={2013}
}
BACKGROUND Ruxolitinib, a Janus kinase 1 and 2 inhibitor, demonstrated improvements in spleen volume, symptoms, and survival over placebo and best available therapy in intermediate-2 or high-risk myelofibrosis patients with baseline platelet counts ≥100 × 109/L in phase III studies. The most common adverse events were dose-dependent anemia and thrombocytopenia, which were anticipated because thrombopoietin and erythropoietin signal through JAK2. These events were manageable, rarely leading to… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
29 Citations
22 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Long-term intervention effects on bone marrow morphology in myelofibrosis: patients treated with ruxolitinib and best available therapy

  • H Kvasnicka, J Thiele, +4 authors S Verstovsek
  • Haematologica 2013,
  • 2013
1 Excerpt

Long - term safety , efficacy , and survival findings from COMFORT - II , a phase 3 study comparing ruxolitinib with best available therapy ( BAT ) for the treatment of myelofibrosis ( MF )

  • F Cervantes, Kiladjian J-J, +12 authors CN Harrison
  • Blood
  • 2012

Long-term safety, efficacy, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis

  • F Cervantes, J-J Kiladjian, +12 authors CN Harrison
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…